Stellar Pharmaceuticals, Inc., a Canada-based developer and marketer of pharmaceutical products, has entered into an exclusive license agreement with Sigmar Italia S.p.A., an Italy-based specialty pharmaceutical sales and marketing company, for the distribution and sale of Uracyst(R) product in Italy. Uracyst(R) is Stellar's proprietary urology product used in the treatment of interstitial cystitis and painful bladder syndrome.
Under the terms of the agreement, Sigmar would pay Stellar an upfront licensee fee, plus a specified transfer price in exchange for the rights to Uracyst(R).
The agreement has an initial five-year term and might be renewed for an additional three-year term with the mutual agreement of Stellar and EuroCept.
No comments:
Post a Comment